Progression-free survival in DUO per investigator assessment, comparing duvelisib with ofatumumab. BID, twice a day; DUV, duvelisib; OFA, ofatumumab. See the complete Figure 1 in the article by Flinn et al that begins on page 2446.
Progression-free survival in DUO per investigator assessment, comparing duvelisib with ofatumumab. BID, twice a day; DUV, duvelisib; OFA, ofatumumab. See the complete Figure 1 in the article by Flinn et al that begins on page 2446.